Short donor leukocyte telomere length

1. Short donor leukocyte telomere length is associated with CD8+CD57+HLA-DR− cell abundance in humans.

   “Immune cell profiling showed that older donors with short LTL had more CD8+CD57+HLA-DR− cells.”

   HumansOlder allo-HSCT donors with short LTL

   Donor leukocyte telomere length emerges as a prognostic factor for transplantation outcomes

   Innovation (Cambridge (Mass.))·24 Oct 2025

More on CD8+CD57+HLA-DR− cell abundance

1. Short donor leukocyte telomere length is associated with relapse-free survival in humans (Relapse or death aHR 1.53, 95% CI 1.06–2.20).

   “worse RFS (aHR = 1.53; 95% CI, 1.06-2.20) compared with recipients of grafts from donors <40 years.”

   HumansAllo-HSCT recipients; older donors with short LTL compared with younger donorsn = 1,049

   Donor leukocyte telomere length emerges as a prognostic factor for transplantation outcomes

   Innovation (Cambridge (Mass.))·24 Oct 2025

1. Short donor leukocyte telomere length is associated with overall survival in humans (Mortality aHR 1.76, 95% CI 1.20–2.58).

   “worse OS (aHR = 1.76; 95% CI, 1.20-2.58)”

   HumansAllo-HSCT recipients; older donors with short LTL compared with younger donorsn = 1,049

   Donor leukocyte telomere length emerges as a prognostic factor for transplantation outcomes

   Innovation (Cambridge (Mass.))·24 Oct 2025

1. Short donor leukocyte telomere length is associated with acute leukemia relapse in humans (aHR 1.51, 95% CI 1.04–2.19).

   “had higher CIR (adjusted hazard ratio [aHR] = 1.51; 95% confidence interval [CI], 1.04-2.19)”

   HumansAllo-HSCT recipients; older donors with short LTL compared with younger donorsn = 1,049

   Donor leukocyte telomere length emerges as a prognostic factor for transplantation outcomes

   Innovation (Cambridge (Mass.))·24 Oct 2025

More on Acute leukemia relapse